Conditional approval for Hansa’s kidney transplant drug
Idefirix is an immunosuppressant that reduces the level of donor specific antibodies, thus enabling transplantation
Read More
Tag: Hansa
EMA accepts marketing authorisation applications for Idefirix and Xospata
European regulators have accepted for review marketing authorisation applications for Hansa’s Idefirix and Astellas’ Xospata.
Read More
